Rosario Martinez-Vega1, Nicole L De La Mata2,3, Nagalingeswaran Kumarasamy4, Penh Sun Ly5, Kinh Van Nguyen6, Tuti P Merati7, Thi Thanh Pham8, Man Po Lee9, Jun Yong Choi10, Jeremy L Ross11, Oon Tek Ng1. 1. Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore. 2. The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. 3. Present address: Sydney School of Public Health, Sydney Medical School, The University of Sydney, Camperdown, NSW, Australia. 4. YRG CARE Medical Centre, VHS, Chennai, India. 5. National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. 6. National Hospital for Tropical Diseases, Hanoi, Vietnam. 7. Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia. 8. Infectious Disease Department, Bach Mai Hospital, Hanoi, Vietnam. 9. Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China. 10. Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea. 11. TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
BACKGROUND: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. METHODS: All HIV-positive adult patients initiating first-line ART in 2003-2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan-Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. RESULTS: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003-2005 to 87.9% (95% CI 87.1, 88.6%) in 2010-2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003-2005 to 86.2% (95% CI 84.7, 87.6%) in 2010-2013. CONCLUSIONS: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.
BACKGROUND: The durability of first-line regimen is important to achieve long-term treatment success for the management of HIV infection. Our analysis describes the duration of sequential ART regimens and identifies the determinants leading to treatment change in HIV-positive patients initiating in Asia. METHODS: All HIV-positive adult patients initiating first-line ART in 2003-2013, from eight clinical sites among seven countries in Asia. Patient follow-up was to May 2014. Kaplan-Meier curves were used to estimate the time to second-line ART and third-line ART regimen. Factors associated with treatment durability were assessed using Cox proportional hazards model. RESULTS: A total of 16,962 patients initiated first-line ART. Of these, 4,336 patients initiated second-line ART over 38,798 person-years (pys), a crude rate of 11.2 (95% CI 10.8, 11.5) per 100 pys. The probability of being on first-line ART increased from 83.7% (95% CI 82.1, 85.1%) in 2003-2005 to 87.9% (95% CI 87.1, 88.6%) in 2010-2013. Third-line ART was initiated by 1,135 patients over 8,078 pys, a crude rate of 14.0 (95% CI 13.3, 14.9) per 100 pys. The probability of continuing second-line ART significantly increased from 64.9% (95% CI 58.5, 70.6%) in 2003-2005 to 86.2% (95% CI 84.7, 87.6%) in 2010-2013. CONCLUSIONS: Rates of discontinuation of first- and second-line regimens have decreased over the last decade in Asia. Subsequent regimens were of shorter duration compared to the first-line regimen initiated in the same year period. Lower CD4+ T-cell count and the use of suboptimal regimens were important factors associated with higher risk of treatment switch.
Authors: Laurence Slama; Xiuhong Li; Todd Brown; Lisa P Jacobson; Gilles Pialoux; Bernard Macatangay; Robert K Bolan; John Phair; Frank J Palella Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Jose Gatell; Dominique Salmon-Ceron; Adriano Lazzarin; Eric Van Wijngaerden; Francisco Antunes; Clifford Leen; Andrzej Horban; Victoria Wirtz; Linda Odeshoo; Monique Van den Dungen; Claudia Gruber; Emilio Ledesma Journal: Clin Infect Dis Date: 2007-04-25 Impact factor: 9.079
Authors: José R Valdez Madruga; Isabel Cassetti; Jamal Muhamad A H Suleiman; Arnaldo Etzel; Lijie Zhong; Charles B Holmes; Andrew K Cheng; Jeffrey Enejosa Journal: HIV Clin Trials Date: 2007 Nov-Dec
Authors: Margaret T May; Jonathan A C Sterne; Dominique Costagliola; Caroline A Sabin; Andrew N Phillips; Amy C Justice; François Dabis; John Gill; Jens Lundgren; Robert S Hogg; Frank de Wolf; Gerd Fätkenheuer; Schlomo Staszewski; Antonella d'Arminio Monforte; Matthias Egger Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Sophie Abgrall; Suzanne M Ingle; Margaret T May; Dominque Costagliola; Patrick Mercie; Matthias Cavassini; Joanne Reekie; Hasina Samji; M John Gill; Heidi M Crane; Jan Tate; Timothy R Sterling; Andrea Antinori; Peter Reiss; Michael S Saag; Michael J Mugavero; Andrew Phillips; Christian Manzardo; Jan-Christian Wasmuth; Christoph Stephan; Jodie L Guest; Juan Luis Gomez Sirvent; Jonathan A C Sterne Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: J Ross; A Jiamsakul; N Kumarasamy; I Azwa; T P Merati; C D Do; M P Lee; P S Ly; E Yunihastuti; K V Nguyen; R Ditangco; O T Ng; J Y Choi; S Oka; A H Sohn; M Law Journal: HIV Med Date: 2020-11-05 Impact factor: 3.180